41,700 Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Acquired by KLP Kapitalforvaltning AS

KLP Kapitalforvaltning AS purchased a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 41,700 shares of the specialty pharmaceutical company's stock, valued at approximately $1,508,000. KLP Kapitalforvaltning AS owned approximately 0.08% of Supernus Pharmaceuticals as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Raymond James Financial Inc. acquired a new stake in Supernus Pharmaceuticals in the fourth quarter valued at $6,847,000. Great Lakes Advisors LLC acquired a new stake in Supernus Pharmaceuticals in the 4th quarter valued at about $6,131,000. American Century Companies Inc. grew its position in shares of Supernus Pharmaceuticals by 9.2% in the fourth quarter. American Century Companies Inc. now owns 1,140,705 shares of the specialty pharmaceutical company's stock valued at $41,248,000 after purchasing an additional 95,777 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in Supernus Pharmaceuticals by 14.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 712,395 shares of the specialty pharmaceutical company's stock worth $22,212,000 after buying an additional 91,354 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in Supernus Pharmaceuticals by 5.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company's stock worth $46,218,000 after purchasing an additional 74,438 shares in the last quarter.

Remove Ads

Supernus Pharmaceuticals Stock Performance

Supernus Pharmaceuticals stock traded up $1.14 during trading on Wednesday, reaching $32.82. The company had a trading volume of 373,123 shares, compared to its average volume of 479,609. Supernus Pharmaceuticals, Inc. has a 12-month low of $25.53 and a 12-month high of $40.28. The stock's 50 day moving average price is $34.81 and its two-hundred day moving average price is $35.05. The firm has a market capitalization of $1.83 billion, a price-to-earnings ratio of 30.67 and a beta of 0.84.

Insider Activity

In related news, VP Padmanabh P. Bhatt sold 700 shares of the firm's stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $39.62, for a total value of $27,734.00. Following the transaction, the vice president now owns 10,149 shares in the company, valued at approximately $402,103.38. This trade represents a 6.45 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Jonathan Rubin sold 927 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $39.15, for a total transaction of $36,292.05. Following the transaction, the senior vice president now directly owns 7,853 shares in the company, valued at approximately $307,444.95. This trade represents a 10.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 11,104 shares of company stock valued at $440,263 in the last ninety days. Company insiders own 9.30% of the company's stock.

Analyst Upgrades and Downgrades

SUPN has been the topic of a number of recent research reports. Cantor Fitzgerald restated a "neutral" rating and issued a $36.00 target price on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th. StockNews.com upgraded shares of Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Tuesday.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.